DCTD Programs
DCTD Active Grants Funded in 2023
Grant Mechanisms
DP2 = Institutional Training and Director Program Projects — NIH Director’s New Innovator Awards
OT2 = Other Transactions — Research Project Other Transaction Award
P01 = Research Program Projects and Centers — Research Program Projects
P20 = Research Program Projects and Centers — Exploratory Grants
P50 = Research Program Projects and Centers — Specialized Center
R00 = Research Projects — Research Transition Award
R01 = Research Project Grant
R03 = Small Research Grant
R13 = Research Projects — Conference
R15 = Research Projects — Research Enhancement Awards
R21 = Research Projects — Exploratory/Developmental Grant
R33 = Research Projects — Exploratory/Developmental Grants Phase II
R35 = Research Projects — Outstanding Investigator Award
R37 = Research Projects — Method to Extend Research in Time (MERIT) Award
R56 = Research Projects — High Priority, Short Term Project Award
R61 = Research Projects — Phase 1 Exploratory/Developmental Grant
R50 = Research Projects — Research Specialist Award
U01 = Research Project — Cooperative Agreement
U10 = Cooperative Clinical Research — Cooperative Agreements
U19 = Cooperative Agreements — Research Program Cooperative Agreements
U24 = Resource-Related Research Project — Cooperative Agreement
U2C = Resource-Related Research Multi-Component Projects and Centers Cooperative Agreements
U54 = Specialized Center — Cooperative Agreement
UG1 = Clinical Research Cooperative Agreements — Single Project
UG3 = Phase 1 Exploratory/Developmental Cooperative Agreement
UH2 = Exploratory/Developmental Cooperative Agreement Phase I
UH3 = Exploratory/Developmental Cooperative Agreement Phase II
UM1 = Research Project with Complex Structure Cooperative Agreement
*Percentages may not total 100% due to rounding
About the Director
James H. Doroshow, M.D., FACP, has been the Director of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), since 2004. He is responsible for integrating the activities of DCTD with NCI’s other divisions and offices, as well as extramural scientists and clinicians, patient advocates, and professional cancer organizations. More…